Drugmakers are more likely to benefit in the long run from partnerships and outsourcing rather than relying solely on in-house research and development, according to a report by the Tufts Center for the Study of Drug Development. "Moving forward, no company -- big, medium or small pharma, or biotech -- will develop new drugs entirely alone," Kenneth Kaitin, director of the Tufts Center.

Related Summaries